


Data Sheet

Product Name:	IAXO-102
Cat. No.:	CS-0089755
CAS No.:	1115270-63-7
Molecular Formula:	C35H71NO5
Molecular Weight:	585.94
Target:	Toll-like Receptor (TLR)
Pathway:	Immunology/Inflammation
Solubility:	Ethanol : 50 mg/mL (85.33 mM; Need ultrasonic); DMSO : < 1 mg/mL (insoluble or slightly soluble)



BIOLOGICAL ACTIVITY:

IAXO-102 is a **TLR4** antagonist which negatively regulates TLR4 signalling. It inhibits MAPK and p65 NF-κB phosphorylation and expression of TLR4 dependent proinflammatory protein. IAXO-102 also prevents experimental abdominal aortic aneurysm development^[1]. IC50 & Target: TLR4^[1] **In Vitro:** IAXO-102 (1-10 μM, for 2 hours) inhibits MAPK and p65 NF-κB phosphorylation in human umbilical vein endothelial (HUVEC) cells^[1].

IAXO-102 (10 μM, for 17 hours) suppresses LPS induced proinflammatory proteins MCP-1 and IL-8 production in HUVEC^[1]. **In Vivo:** IAXO-102 (3 mg/kg/day, s.c. for 28 days) significantly retards Angiotensin II induced increase in aortic diameter in mice^[1].

References:

[1]. Huggins C, et al. A novel small molecule TLR4 antagonist (IAXO-102) negatively regulates non-hematopoietic toll like receptor 4 signalling and inhibits aortic aneurysms development. *Atherosclerosis*. 2015 Oct;242(2):563-70.

CAIndexNames:

α-D-Glucopyranoside, methyl 6-amino-6-deoxy-2,3-di-O-tetradecyl-

SMILES:

CCCCCCCCCCCCCO[C@@H]1[C@H]([C@@H]([C@@H]([C@@H](CN)O[C@@H]1OC)O)O)OCCCCCCCCCCCCC

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 732-484-9848 Fax: 888-484-5008 E-mail: sales@ChemScene.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA